Abstract
Vorolanib is an oral tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor rec......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
